Creative Studio Powster Announces Innovation for Movie Studios
Movie studios can now sell movie theater tickets on their official movie websites. Cinemagoers can now buy tickets directly on websites such as www.deadpool.com, www.adrift.movie, www.equalizer.movie, and the upcoming site for Mission: Impossible - Fallout. These ticketing portals are activated across all social media, meaning studios can now sell their own tickets from their Facebook, Twitter, Instagram and other social media channels.
Powster creates movie websites for all six major studios and launches over 170 sites every month. After successful Beta testing, Powster has now enabled full ticketing on these movie websites so that cinemagoers can complete the entire purchasing journey without redirecting the user to a third-party website.
Powster’s ability to launch full-ticketing at scale is in part related to movieXchange’s MX Tickets service, Vista Group’s new global ticketing platform allowing ticket sellers to integrate with and transact against all exhibitors. By integrating the full payment process into the movie site, Powster has improved the user journey of purchasing a ticket letting users purchase directly on the movie website, making going to the cinema easier than ever.
The Powster ticketing model is unique to the industry. Payments are deposited directly with the theater, eliminating the administrative hang-ups previously associated with third-party ticket sales. For studios, Powster ticketing ensures visibility and measurement of the entire purchasing process culminating in actual ticket sales.
Hollywood distributors and industry partners Twentieth Century Fox Film, Paramount Pictures, STXfilms, RealD, Annapurna, The Orchard, CBS Films, Magnolia Pictures, Amazon Studios, ShortsTV, FilmRise, GKIDS, Gunpowder & Sky, and more have partnered with Powster and integrated full ticketing flow into their systems.
Powster CEO Ste Thompson says, “We have researched into the best solution for both movie theaters and movie distributors. Our solution equally benefits both parties by enabling the movie studio to optimise their advertising and the movie theater to retain the customer.”
Over 20 theaters have signed on to implement Full Ticketing upon its release. B+B Theatres, New Vision Cinemas, Celebration Theatres, Starlight Cinemas, Paramount 5, D’Place Entertainment, Envision Cinemas Bar & Grille, Main Street Theatres, Midwest Movies, FatCats Entertainment, and Tristone Cinemas are early adopters of the new system. Full Ticketing will reach over 27,000 screens in its first month(s) of processing.
Powster ticketing can be integrated into social platforms, such as Facebook, Snapchat, and Instagram, so users can complete their ticket purchase without leaving the site. Full ticketing has also been built into Powster’s Facebook Messenger experiences, where users can set reminders, watch movie trailers, and organize showtimes with friends all without leaving Messenger.
Powster will be exhibiting Full Ticketing, AR capabilities, and Messenger integration at CineEurope, in the main foyer, across from the trade show registration booth. If you would like to arrange a chat in advance, please email PR and Marketing Coordinator Samantha Robinson - email@example.com.
POWSTER, part of the Vista Group of companies (NZX: VGL) (ASX: VGL), is a creative and innovation studio operating in London and Los Angeles. The business provides creative services to the film and music industry and creates products to help engage users with entertainment content. The global leader in film distribution marketing websites, POWSTER creates more than 170 destinations a month for 100+ movie distributors in over 40 countries. The POWSTER movie platform enables over thirty-five million cinemagoers a month to discover showtimes on official movie websites.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 14:00 | Tiedote
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 11:10 | Tiedote
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 18:13 | Tiedote
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00 | Tiedote
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41 | Tiedote
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00 | Tiedote
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme